Article

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy

2010-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fea28c6b-2d49-5c5c-8684-39ad3d9d4df7
DOI: 10.1186/bcr2545
PMCID: PMC2875610

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapyDOI 10.1186/bcr2545Read

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical RelevanceSemantic proximity Read

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.Semantic proximity Read

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.Semantic proximity Read

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read

Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.Semantic proximity Read

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read